UGT1A5

UDP-glucuronosyltransferase 1-5 (UGT1A5) is a phase II metabolic enzyme encoded by the UGT1A5 gene. It catalyzes glucuronic acid conjugation to lipophilic substrates—including drugs, environmental toxins, and endogenous molecules—boosting their water solubility for renal or biliary excretion. No widely accepted common aliases exist beyond its systematic name.
UGT1A5 participates in xenobiotic detoxification pathways. Genetic polymorphisms alter its activity, impacting drug efficacy/toxicity (e.g., some chemotherapeutics). Impaired function may lead to carcinogen accumulation, linking it to gastrointestinal cancers. Current research focuses on variant-guided personalized dosing and modulators targeting UGT1A5 for therapeutic optimization.